Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W3GL
|
|||
| Former ID |
DNC005420
|
|||
| Drug Name |
SR-147778
|
|||
| Synonyms |
Surinabant; SR-147778; UNII-SF8R9VCB0X; 288104-79-0; SR147778; SR 147778; SF8R9VCB0X; CHEMBL189676; Surinabant [INN]; DSSTox_CID_27357; DSSTox_RID_82293; DSSTox_GSID_47357; SCHEMBL675894; GTPL9233; DTXSID2047357; CHEBI:125484; ZINC1549068; Tox21_300239; BDBM50171290; DB13070; NCGC00254070-01; NCGC00247959-01; 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide; LS-193786; FT-0766481; CAS-288104-79-0; BRD-K09557221-001-01-6
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H23BrCl2N4O
|
|||
| Canonical SMILES |
CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br
|
|||
| InChI |
1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31)
|
|||
| InChIKey |
HMXDWDSNPRNUKI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 288104-79-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:125484
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Modulator | [2] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00239174) A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients. U.S. National Institutes of Health. | |||
| REF 2 | Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.